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Abstract: Prasugrel (CS-747, LY640315) is a novel member of the thienopyridine class of 
oral anti-platelet agents (also including ticlopidine and clopidogrel). Like other thienopyridines, 
prasugrel is a prodrug that is inactive in vitro. Prasugrel’s conversion to its active metabolite 
is more rapid and efﬁ  cient than that of other thienopyridines, with a less strict dependence 
on speciﬁ  c cytochrome P-450 enzymes. Prasugrel’s active metabolite (R-138727) binds 
speciﬁ  cally and irreversibly to the platelet P2Y12 purinergic receptor, thus inhibiting 
ADP-mediated platelet activation and aggregation. Preclinical data and early clinical data in 
healthy subjects showed greater platelet inhibition and consistency with prasugrel as opposed 
to clopidogrel. Clinical studies in patients with cardiovascular disease conﬁ  rmed the greater 
efﬁ  cacy of prasugrel compared with clopidogrel. Collectively, these phase 1/1b studies and 
a phase 2 study (JUMBO-TIMI 26) aided in dose selection for the phase 3 trial (TRITON-
TIMI 38) in patients with acute coronary syndrome undergoing percutaneous coronary inter-
vention. This trial once again conﬁ  rmed the greater anti-platelet effect of prasugrel, but also 
highlighted a higher risk of bleeding, even fatal. Another phase 2 trial (PRINCIPLE-TIMI 44) 
compared prasugrel and high-dose clopidogrel in patients undergoing cardiac catheterization 
for planned PCI.
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Platelets and atherothrombosis
Platelets are one of the main actors in the spontaneous process of atherothrombosis 
and in post-coronary stenting acute thrombosis.1 Following the initial adhesion of 
platelets to collagen, von Willebrand factor and other subendothelial proteins in the 
site of vascular injury or ruptured atherosclerotic plaque, platelet activation maintains 
itself through the release of adenosine diphosphate (ADP), thromboxane A2 (TXA2) 
and other mediators. The interaction of ADP with the G protein-coupled purinergic 
receptors, P2Y1 and P2Y12, leads to further activation of platelet functions, such as 
aggregation, shape change and secretion. Activation of this process in coronary arteries 
leads to the formation of platelet-rich thrombi, which in turn initiates the cascade of 
vascular occlusion, tissue ischemia and myocardial necrosis that is known under the 
collective name of acute coronary syndrome (ACS).
Also, when patients with coronary atherosclerotic disease are treated with 
percutaneous coronary intervention (PCI), there is a signiﬁ  cant risk of platelet activation 
and aggregation at the site of balloon dilation and stenting, which could lead to 
stent-associated thrombosis (SAT).2 Accordingly, antiplatelet drugs have been shown 
to be useful in reducing such complications.3,4
According to this, anti-platelet agents are widely used for prevention and therapy 
in patients with atherothrombotic coronary disease, and to prevent SAT after 
performing PCI.Vascular Health and Risk Management 2009:5 322
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Currently used thienopyridines
Currently used thienopyridines, ticlopidine and clopidogrel, 
are both prodrugs that need to be converted to an active 
metabolite that binds irreversibly to the P2Y12 receptor, thus 
preventing ADP binding and ADP mediated platelet activa-
tion and aggregation.5 Of the two, clopidogrel is the more 
commonly used, due to its improved tolerability and lower 
incidence of hematologic side-effects. Numerous studies 
have demonstrated the safety and efﬁ  cacy of dual antiplatelet 
therapy – aspirin co-administered with either ticlopidine or 
clopidogrel – in improving the clinical outcome of patients 
with ACS and reducing the risk of early SAT in patients 
undergoing PCI (clopidogrel being a better choice for the 
latter, by virtue of its greater safety and tolerability over 
ticlopidine). Large trials such as CREDO or PCI-CURE con-
ﬁ  rmed the superiority of dual antiplatelet therapy (aspirin and 
clopidogrel) in preventing major cardiovascular events over 
aspirin and placebo.3,4 However, clopidogrel exhibits some 
limitations such as modest antiplatelet activity, a signiﬁ  cant 
interpatient variability and delayed onset of action. Some 
clinical evidence suggests that patient with reduced response 
to clopidogrel (even at higher loading dose regimens) are at 
increased risk of major cardiovascular events and SAT after 
undergoing PCI.6,7
Investigational agents
Prasugrel (CS-747, LY640315) is a novel investigational 
drug belonging to the thienopyridines class of anti-
platelet agents.8 In preclinical and clinical studies it has 
demonstrated to be an orally active inhibitor of platelet 
activation and aggregation, having more potent activity, 
lesser interpatient variability and faster onset of action as 
compared to clopidogrel and ticlopidine. Initial testing in 
rats demonstrated that prasugrel produced dose-related 
inhibition of platelet activity with a potency approximately 
10- and 100-fold greater than clopidogrel and ticlopidine, 
respectively. This can be related to more efﬁ  cient forma-
tion of prasugrel’s active metabolite as opposed to that of 
clopidogrel. The active metabolites of both drugs not only 
inhibit ADP-mediated platelet aggregation, but also other 
consequences of platelet activation, such as GP IIb/IIIa 
activation, platelet-leukocyte aggregate formation, platelet 
procoagulant activity, and inhibition of platelet throm-
boinﬂ  ammatory markers.9
Pharmacology
Prasugrel first undergoes rapid hydrolysis by esterases, 
thus forming thiolactone (R-95913), which is in turn 
oxidized by intestinal and hepatic cythochrome P 450 
(CYP), which causes the opening of the ring structure and 
the formation of the active metabolite (R-138727), which 
contains an –SH group. The active metabolite becomes 
detectable in plasma after 15 minutes, and reaches peak 
concentration at 30 minutes after dosing. The main pathway 
for the elimination of the active metabolite in humans is renal 
excretion.10 The main cytochrome isoenzymes responsible 
for the formation of the active metabolite are CYP3A 
and CYP2B6, with lesser contribution by CYP2C9 and 
CYP2C19.11 The latter two, on the other hand, play a major 
role in the formation of clopidogrel’s active metabolite; this 
would explain why common loss-of-function mutations in 
these loci greatly affects clopidogrel while barely interfer-
ring with the formation of prasugrel’s active metabolite.12 
Furthermore, co-administration of potent CYP3A inhibitors 
such as ketoconazole, albeit signiﬁ  cantly reducing R-138727 
maximum concentration, does not affect the area under the 
time-concentration curve nor prasugrel’s antiplatelet effects.13 
Prasugrel’s metabolites do not appear to inhibit cythochrome-
mediated metabolism of other co-administered drugs.
Phase 1 clinical trials
Three early phase 1 trials confirmed the results of the 
preclinical studies on animals, ﬁ  nding prasugrel to be 10 times 
more potent than clopidogrel, and consistently so, as opposed 
to clopidogrel’s signiﬁ  cant variability in response.14–16 These 
results were further proved by a crossover study in healthy, 
aspirin-free subjects, which found prasugrel to reach higher 
levels in the active metabolite concentration, thus justifying the 
greater inhibition of platelet aggregation. Another interesting 
ﬁ  nding was that clopidogrel non-responders had good response 
to prasugrel when crossed over.17 Another trial,18 performed 
on healthy subjects, had the trial drug co-administered with 
aspirin: once again, prasugrel proved to be more potent and 
produced greater inhibition of platelet aggregation. Overall, at 
the dosing regimens tested, prasugrel was well tolerated, hema-
tomas and minor bleeding being the most reported adverse 
events. No evidence of hepatic or central nervous system 
toxicity, neutropenia, thrombocytopenia or QT-prolongation 
were reported.
The ﬁ  rst patient study was a phase 1b dose-ranging 
study of prasugrel versus clopidogrel in patients with stable 
coronary artery disease already taking aspirin.19 Prasugrel 
loading doses of 40 and 60 mg produced signiﬁ  cantly higher 
inhibition of platelet aggregation than clopidogrel loading 
dose (300 mg), and maintenance dosing maintained stable, 
dose-dependent inhibition of platelet aggregation that were Vascular Health and Risk Management 2009:5 323
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signiﬁ  cantly higher than clopidogrel maintenance dose of 
75 mg for the prasugrel 10 and 15 mg maintenance dosing. 
Safety was comparable in the two groups: although an 
increase in minor bruising and bleeding events was found 
in the prasugrel 15 mg maintenance dosing group, a post-
hoc analysis found no relation between higher inhibition of 
platelet aggregation and bleeding; the study, however, was 
not powered to detect such differences.
Phase 2 clinical trials
JUMBO-TIMI 26 was a phase 2 randomized, dose-ranging, 
double-blind safety trial. 904 patients undergoing elective or 
urgent PCI were randomized to either receive standard clopi-
digrel loading and maintenance doses or one of three different 
prasugrel dosing regimens (40 mg loading dose/7.5 mg 
maintenance dose, 60 mg LD/10 mg MD or 60 mg LD/15 mg 
MD) in co-administration with aspirin.20 Patients were then 
monitored for a 30-days follow-up period for bleeding and 
major adverse cardiac events. Treatment with prasugrel 
resulted in an overall rate of bleeding comparable to that of 
patients treated with clopidogrel, although an increased rate 
of TIMI minimal bleeding events was reported for the high 
dose prasugrel group as opposed to all the other treatment 
groups. Treatment with prasugrel attained a non-signiﬁ  cantly 
lower rate of cardiac adverse events (secondary efﬁ  cacy 
endpoint), primarily driven by a reduction in myocardial 
infarction and urgent reintervention. This study served as a 
foundation for a large phase 3 trial, designed to assess both 
efﬁ  cacy and safety.
Phase 3 clinical trials
TRITON-TIMI 38 was a phase 3 randomized double-blind 
trial. 13,608 patients with an ACS (unstable angina, NSTEMI 
or STEMI) undergoing scheduled PCI were randomized 
to receive either clopidogrel (standard dosing regimen) or 
prasugrel (60 mg loading dose and 10 mg od maintenance 
dose) in addition to aspirin.21 The primary efﬁ  cacy endpoint 
was a composite of death from cardiovascular causes, non-
fatal myocardial infarction and non-fatal stroke during the 
follow up period, while the primary safety endpoints were 
TIMI life-threatening, major or minor bleeding not related to 
coronary artery bypass grafting. Endpoints were evaluated at 
hospital discharge, 30 days, 90 days and then every 3 months 
for up to a 15 months follow up period. Treatment with 
prasugrel resulted in a signiﬁ  cantly reduced rate of primary 
efﬁ  cacy endpoint events (781 in the clopidogrel group, 
12.1%, versus 643 in the prasugrel group, 9.9%; hazard 
ratio 0.81; 95% CI 0.71 to 0.96; p  0.001), especially 
due to a reduction in myocardial infarction. This equals 
a 2.2% absolute reduction and a 19% relative reduction 
of primary efﬁ  cacy endpoints in the prasugrel treatment 
group. The rate of primary safety endpoints, however, was 
signiﬁ  cantly higher in patients who received treatment with 
prasugrel (146 in the prasugrel group, 2.4%, versus 111 in 
the clopidogrel group, 1.8%; hazard ratio 1.32; 95% CI 
1.03 to 1.68; p = 0.03), including fatal (0.4% versus 0.1%, 
p = 0.002) and life-threatening bleeding. The rates of certain 
efﬁ  cacy and safety endpoints were included in a prespeciﬁ  ed 
analysis of net clinical beneﬁ  t (deﬁ  ned as the rate of death 
from any cause, non-fatal myocardial infarction, non-fatal 
stroke, or non-CABG-related non-fatal TIMI major bleeding) 
and the findings were in favor of prasugrel (13.9% of 
patients in the clopidogrel group vs 12.2% in the prasugrel 
group; hazard ratio, 0.87; 95% CI, 0.79 to 0.95; p = 0.004). 
Post-hoc analyses were then performed to identify the sub-
groups of patients who did not have a net clinical beneﬁ  t 
from the use of prasugrel and those who had net clinical 
harm. Patients with clinical history of stroke or transient 
ischemic attack had net clinical harm: they had no evidence 
of clinical beneﬁ  t as evaluated by primary efﬁ  cacy endpoints, 
while exhibiting a signiﬁ  cant trend toward major bleeding 
(including intracranial hemorrhage). Patients 75 years of age 
or older and patients weighing less than 60 kg had no net 
clinical beneﬁ  t, although they did not have net clinical harm 
either; the bleeding rate in these two categories of patients 
was greater, although not statistically signiﬁ  cant. Among 
patients who did not fall in any of these three categories, 
prasugrel exhibited greater efﬁ  cacy than clopidogrel, while 
the bleeding rate was comparable among the two.
Comparison with higher clopidogrel 
dosing regimens
PRINCIPLE-TIMI 44 was a phase 2 randomized, 
double-blind, 2-step crossover study in which prasugrel 
was compared with high-dose clopidogrel in patients 
undergoing cardiac catheterization for planned PCI.22 
Patients were randomized to receive either a clopidogrel 
600 mg or prasugrel 60 mg loading dose one hour before 
undergoing heart catheterization. After PCI, patients were 
then assigned to receive a once-daily maintenance dose of 
either clopidogrel 150 mg or prasugrel 10 mg, according to 
the assigned treatment group, for a period of 14 days. From 
day 15, after data collection and endpoint evaluation, they 
were then switched to receive the alternate maintenance 
therapy for an additional 14 days. Inhibition of platelet 
aggregation was tested both after the loading dose and during Vascular Health and Risk Management 2009:5 324
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the maintenance period. Treatment with prasugrel resulted 
in a quicker (30 min) and persistently higher inhibition of 
platelet aggregation, after the loading dose and during all of 
the treatment period.
Unpublished and ongoing trials
Further clinical trials have been, or are being conducted 
to establish an advantage of prasugrel over clopidogrel by 
means of its pharmacodynamic effects (inhibition of platelet 
aggregation measured by various laboratory assays), to 
evaluate safety and tolerability of switching treatment from 
clopidogrel to prasugrel and to further assess dosing regimens 
of both drugs.
Conclusions
Prasugrel is a potent novel thienopyridine antiplatelet agent 
that preclinical trials so far have shown to achieve greater, 
faster and less variable response in terms of inhibition of 
platelet aggregation as compared with clopidogrel due to 
more efﬁ  cient generation of the active metabolite. Clini-
cal trials, in turn, have shown prasugrel to be superior to 
clopidogrel in preventing major cardiac adverse events in 
patients with ACS undergoing PCI, while attaining a lesser 
rate of non-responders. On the other hand, the TRITON-TIMI 
38 trial has shown that treatment with prasugrel bears a 
signiﬁ  cant increase in the bleeding rate, including major, 
life-threatening and fatal events. This raises an obvious safety 
issue, and although post-hoc analyses seem to have identi-
ﬁ  ed those categories of patients that are at increased risk for 
bleeding, this point needs to be further investigated.
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